SP-MET-2

N/A

Report date: 2025/06/11 20:01:15

NME

Base Information

Drug NameSP-MET-2

Drug Alias NameS100A4 receptor antagonist (Supratek)antimetastatic agent (Supratek)SP-MET-X2SP-MET-2

ClassificationSmall molecules

Mechanisms of ActionProtein S100-A4 modulatorsAngiogenesis inhibitorsMetastasis inhibitors

TargetsProtein S100-A4

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesSupratek Pharma

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesSupratek Pharma

Active IndicationsN/A

Inactive IndicationsNeoplasms

ATC CodeN/A